Burgess Michael F. 4
4 · SpringWorks Therapeutics, Inc. · Filed Jan 10, 2022
Insider Transaction Report
Form 4
Burgess Michael F.
Head of Research & Development
Transactions
- Award
Common Stock
2022-01-06+15,674→ 43,174 total - Award
Stock Option (Right to Buy)
2022-01-06+48,852→ 48,852 totalExercise: $59.46Exp: 2032-01-06→ Common Stock (48,852 underlying)
Footnotes (2)
- [F1]This transaction represents a grant of restricted stock units ("RSUs"). The RSUs shall vest as follows: thirty three percent (33%) to vest on January 6, 2023, another thirty three percent (33%) to vest on January 6, 2024 and the remaining thirty four percent (34%) to vest on January 6, 2025, such that the restricted stock awards are fully vested on January 6, 2025.
- [F2]This option shall vest in 48 equal monthly installments subject to continued service to the company by the Reporting Person.